Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a] pyrimidines as potential anti-chikungunya agents by Fares, Mohamed et al.
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: Part B Faculty of Science, Medicine and Health 
1-1-2020 
Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a] 
pyrimidines as potential anti-chikungunya agents 
Mohamed Fares 
University of Wollongong, mm342@uowmail.edu.au 
Patrick McCosker 




See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers1 
Publication Details Citation 
Fares, M., McCosker, P., Alsherbiny, M., Willis, A., Clark, T., Neyts, J., Jochmans, D., & Keller, P. A. (2020). 
Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a] pyrimidines as potential anti-
chikungunya agents. Faculty of Science, Medicine and Health - Papers: Part B. Retrieved from 
https://ro.uow.edu.au/smhpapers1/1198 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a] pyrimidines as 
potential anti-chikungunya agents 
Abstract 
This journal is The Royal Society of Chemistry. Convergent and convenient regioselective synthesis of 
novel thiazolo[2,3-a]pyrimidine derivatives was accomplished using the one-pot reaction of 
6-ethylthiouracil, bromoacetic acid, anhydrous sodium acetate, acetic anhydride, acetic acid and suitable 
aldehyde. X-ray crystallographic study reveals the presence of the Z configuration of only one regioisomer 
confirmed by computational studies as being the most likely isomer present. 
Publication Details 
Metwaly, M., McCosker, P., Alsherbiny, M., Willis, A., Clark, T., Neyts, J., Jochmans, D. & Keller, P. (2020). 
Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a] pyrimidines as potential anti-
chikungunya agents. RSC Advances, 10 (9), 5191-5195. 
Authors 
Mohamed Fares, Patrick McCosker, Muhammad Alsherbiny, Anthony Willis, Timothy Clark, Johan Neyts, 
Dirk Jochmans, and Paul A. Keller 
This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers1/1198 
Regioselective convergent synthesis of 2-arylidene
thiazolo[3,2-a]pyrimidines as potential anti-
chikungunya agents†
Mohamed Fares, *ab Patrick M. McCosker, ac Muhammad A. Alsherbiny, d
Anthony C. Willis,e Timothy Clark, c Johan Neyts, f Dirk Jochmans f
and Paul A. Keller *a
Convergent and convenient regioselective synthesis of novel thiazolo[2,3-a]pyrimidine derivatives was
accomplished using the one-pot reaction of 6-ethylthiouracil, bromoacetic acid, anhydrous sodium
acetate, acetic anhydride, acetic acid and suitable aldehyde. X-ray crystallographic study reveals the
presence of the Z conﬁguration of only one regioisomer conﬁrmed by computational studies as being
the most likely isomer present.
Arboviruses mainly use arthropod vectors for transmission
between hosts and they are considered a growing global health
threat.1,2 This arises from the increasing number of travellers,
from 450 million in 1990 to nearly 1.4 billion in 2018, and
consequently travel-related diseases incidence has increased
signicantly.3 Chikungunya virus (CHIKV) (Alphavirus genus,
family Togaviridae) is one of the prevalent tropical alphaviruses
that is transmitted by Aedes mosquitoes.4,5 Aer an incubation
period of 2–4 days, symptoms start with the onset of high fever
and severe persistent joint pain that may last for weeks to
years.6,7 Other symptoms of chikungunya fever (CHIKF) include
headache, vomiting, rash, myalgia (muscle pain), photophobia
and maculopapular rash.6,8 Unlike other arbovirus infections,
around 15% of the patients may encounter “silent infections”.6
A variety of strategies have been applied to develop anti-
CHIKV treatments, including vaccines, and for small molecule
inhibitors, random screening, computer aided drug design,
ligand-based drug design, high throughput screening and
genome-wide loss of function screen.9–17 Non-steroidal anti-
inammatory drugs (NSAID) have been used to alleviate the
symptoms of the CHIKF because of the lack of eﬀective
prevention or curing of the viral infection.18 However, so far
there is no vaccine or approved medication to prevent or treat
CHIKV infection.
The recent advances and growing knowledge about the
arboviruses expand our understanding of the CHIKV life cycle,
pathogenesis and infection.1–6 Intensive research in the past 10
years has led to the identication of new chemical scaﬀolds that
might be potential anti-CHIKV agents. Rhodanine I is a thiazo-
lidin-4-one derivative, presenting a scaﬀold that exhibited
broad antiviral activity against HCV, HIV-1 and Chikungunya
(Fig. 1).19 A series of rhodanine derivatives was tested for their
anti-CHIKV activity by a cytopathic eﬀect (CPE) reduction assay
(Fig. 1). The 2-methyl analogue II emerged as the best
compound and displayed excellent activity with submicromolar
Fig. 1 Examples of heterocyclic classes showing anti-CHIKV activity,
including thiazolidin-4-one I and II, pyrimidine III and pyrimidine fused
rings IV and IVa–c.
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EC50 (EC50 ¼ 0.42 mM) against CHIKV. A docking study also
showed good interaction between the ligand and CHIKV nsp2
protease.19
Among the main heterocycles that form the basis of small
molecule inhibitors of CHIKV are the pyrimidine and fused
pyrimidine rings, e.g. III, IV and Va–c (Fig. 1).15,20,21 Recent
reports indicated that hybridization between uracil–coumarin–
arenes III resulted in the discovery of a novel anti-CHIKV scaf-
fold that was found to impede CHIKV replication.20 In an eﬀort
to nd new leads as CHIKV inhibitors, a random screening
identied the [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)ones as
potential candidates.21 Iterative optimization cycles led to the
most potent compound IV with EC50 ¼ 3 mM and a selectivity
index greater than 600 (Fig. 1).21 In 2012, purine-b-lactams Va
and Vb and purine-amino propanol Vc (Fig. 1) conjugates were
screened against nine diﬀerent viruses including CHIKV. The
amino propanol derivative Vc (EC50 ¼ 11.51–17.11 mM) showed
relatively higher activity other than the purine-b-lactam hybrids.
Therefore, the b-lactam was not essential for activity.15
Recently, hybridization of two or more bioactive fragments
has emerged as a concept for the exploration of novel multi-
target acting inhibitors as well as novel anti CHIKV agents
(Fig. 2).15,20,22,23 Therefore, in our ongoing eﬀorts to discover new
scaﬀolds for CHIKV infection, we investigated a molecular
hybridization approach with the fusion of the uracil and the
rhodanine pharmacophoric moieties (Fig. 2).22
The synthetic strategy started with the condensation of ethyl
propionylacetate 1 and thiourea 2 to aﬀord the known 6-ethyl
thiouracil 3 with 69% yield.24,25 Although the synthesis of the
thiazolopyrimidine derivatives from the 6-ethylthiouracil
substrate has not previously been reported, this multicompo-
nent reaction (MCR) was achieved using an analogous proce-
dure26–29 by reacting 3 with the aldehyde, chloroacetic acid,
sodium acetate anhydrous, acetic anhydride and acetic acid in
one pot and at reux for 4 h (Scheme 1).
These conditions consistently gave low yields and two
regioisomers (e.g. chlorobenzaldehyde 8 A : B 16% : 84%), the
latter determined by analysis of the 1H NMR spectrum (Fig. 3) –
attempts to separate the isomers by column chromatography
failed.
Optimization of the reaction involved varying the mode of
addition, replacement of the chloroacetic acid with bromoacetic
acid, and lowering the reaction temperature. This aimed to
favour the formation of the kinetic regioisomer (Z)-A, assumed
to be the desired product, over the thermodynamic regioisomer
(Z)-B (Scheme 2), and resulted in the crystallization of only one
regioisomer from the reaction mix (acetic acid) in each case.
This may be due to the low reactivity and the less regioselectivity
of the chloroacetic acid compared to bromoacetic acid.
From the convergent reaction conditions, four possible
isomers can be formed: the Z or E congurations of structural
isomers A or B – (Z)-A, (E)-A, (Z)-B and (E)-B (Fig. 4). Analysis of
the 1H NMR spectra showed a quartet at 2.48–2.57 ppm
assigned to methylene hydrogens of the ethyl substituent –
these were assigned to structural isomer A as the corresponding
resonances of isomer B are expected to resonate more downeld
(3 ppm) as a result of a deshielding anisotropic eﬀect of the
adjacent carbonyl group of the thiazole ring.
The Z absolute conguration of this class of molecules was
conrmed by X-ray crystallographic analysis of derivative 12
(Fig. 5). This illustrated the planarity of the thiazolopyrimidine
rings with the aryl group, which may be attributed to two
intramolecular hydrogen bonds. The Z-conguration is
presumably stabilized by the two intramolecular hydrogen
bonds between the arylidene H and the oxygen atom of the
thiazole carbonyl group (HB1) and between the sulfur atom and
the aryl hydrogen (HB2). The distance of both hydrogen bonds
is 2.49 and 2.50 A˚, for HB1 and HB2, respectively, and the angles
are 102.81 and 132.94 for HB1 and HB2 respectively.
Fig. 2 Design of the targeted uracil–rhodanine conjugates.
Scheme 1 Reagents and conditions: (i) NaOEt, C2H5OH, 6 h, reﬂux; (ii)
ClCH2COOH, anhydrous CH3COONa, (CH3CO)2, CH3COOH, 4-
chlorobenzaldehyde, reﬂux, 4 h.
Fig. 3 1H NMR spectrum of the MCR product of the two regioisomers
of 8 in a ratio of 1 : 5.































































































To investigate the observed preference for the Z isomer,
density functional theory (DFT) calculations were performed
using the widely applied M06-2X functional with a Dunnings
aug-cc-pVDZ basis set. Compound 6 (Ar ¼ C6H6) was selected
for the theoretical study and all structures were optimised with
modelled acetic acid solvation (SMD). Analysis of the proposed
mechanism indicated a possible alcohol intermediate and
dehydration step preceded the nal Z/E isomer formation, and
to keep the model simple, the calculations have focussed on
these molecules only, maintaining chirality where applicable
(Fig. S1†). Conformer analysis of the alcohol intermediate
indicated a Gibbs free energy of reaction (DrG
0{298 K}) range of
+0.35 to 2.30 kcal mol1 with the Z arranged C1 being the
lowest and the E arranged C2 the highest energy conformers
respectively (Fig. S2†). Analysis of the optimised geometries
gave no indication of hydrogen bond stabilisation for the
alcohol, despite attempts at manually inputting the conforma-
tion. This indicated steric and geometric arrangement of the
alcohol intermediate is more signicant for the energy term.
A stacked ring conformer (C3) was also observed with
a favourable DrG
0{298 K} of 1.30 kcal mol1. To better account
for this interaction, Grimme's dispersion (D3) and geometric
counterpoise (gCP) corrections30 were applied to the energy
term, and the stacked C3 was observed to increase by
+1.29 kcal mol1, whereas C1/C2 increased by +0.87 and
+0.85 kcal mol1 respectively. The similar increase to the energy
term for C1/C2 suggested there are no diﬀerences in dispersion
eﬀects to account for in these conformers. However, the greater
energy change observed with C3was indicative the ring stacking
is not a favourable intramolecular force. Based on the subtle
diﬀerences in energies of the conformers, C1 is the apparent
favoured alcohol intermediate conformer, which is arranged to
dehydrate to the Z isomer.
The transition states of the proposed dehydration reactions
were calculated and the saddle point DrG
0{298 K} were found to
be +32.58 and +30.05 kcal mol1 for the E T1 and Z T2 arranged
transition states respectively (Fig. S3a†). With the D3-gCP
corrections DrG
0{298 K} were +33.51 and +30.90 kcal mol1
for T1 and T2 respectively. The similar increases in energy
(+0.93 and +0.85 kcal mol1) indicated negligible diﬀerences in
dispersion force correction required when comparing T1 and
T2. What was particularly interesting to note, in contrast to the
alcohol intermediate, is the preference of the water leaving
hydrogen bound to the carbonyl. Despite attempts in manually
positioning the water to leave adjacent to the sulfur, and in turn
have H–S interaction, the transition state only converged to
allow hydrogen bonding of the water with the thiazole carbonyl.
Subsequently, it was proposed the principal factor dictating the
favoured transition state is the arrangement of the aryl group, as
the water has apparent preference for leaving trans to the sulfur,
in favour of Z isomer formation.
Subsequent calculation of the product (E)-6 and (Z)-6
isomers indicated DrH
0{298 K} of 2.40 and 6.78 kcal mol1
respectively, which indicts the Z isomer to be thermodynami-
cally favoured, and D3-gCP corrections were in good agreement
(Fig. 6 and S3b†). Comparison of the calculated (Z)-6 structure
with the X-ray crystal structure of compound 12 indicated
similar bond distances of HB1 ¼ 2.43 A˚ and HB2 ¼ 2.50 A˚ for
the proposed intramolecular hydrogen bonds (Fig. 5).
Likewise, the bond angles were in good agreement for HB1
and HB2 calculated at 101.34 and 127.70, compared with
102.81 and 132.94 from the crystal structure, respectively. In
conclusion, although the energy diﬀerences are small between
the investigated reaction pathways, there is a consistent pref-
erence for the Z forming pathway at each step investigated and
this result was reciprocated by D3-gCP energy corrections
(Fig. 6).
The compounds were screened for their antiviral activities in
a viral-cell based assay against Chikungunya virus (Indian
Ocean strain 899) (Table S1†).
Based on the biological results, compounds 6–20 showed
diﬀerent percentages of viral replication inhibition at
Scheme 2 Reactions and conditions: (i) BrCH2COOH, anhydrous
CH3COONa, (CH3CO)2, CH3COOH, 60 C, 3 h; (ii) benzaldehyde,
anhydrous CH3COONa, CH3COOH, 60 C, 2 h. (iii) BrCH2COOH,
anhydrous CH3COONa, (CH3CO)2, CH3COOH, aldehyde, 60 C, 4 h.
Fig. 4 The four possible isomers that can be produced from the MCR
reaction.
Fig. 5 (A) ORTEP diagram of compound 12, (B) representation of
stabilizing hydrogen bonds of the regioisomer (Z)-A.































































































20 mg mL1 with (Z)-7-ethyl-2-((40-methyl-[1,10-biphenyl]-4-yl)
methylene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione
showing the best activity with 58% inhibition of CHIKV repli-
cation. Derivatives 6, 11 and 20 showed 19, 28 and 34% inhi-
bition of viral replication, while rest of the compounds showed
fair or no activity. However, thiazolodione 15 can be considered
as a potential lead compound in our future iterative cycles of
optimization. The compound emerged as the most promising
antiviral among the tested series with EC50 ¼ 42 mM, with IC50 >
250 mM against the breast cancer cell line MCF-7 and the
endothelial human sapiens cell line EA.hy926. Compound 15 is
endowed with p-methylbiphenyl tail functionality which might
interact favourably with the target. Our outlook will include
optimization of compound 15 with the prime aim to nd safe
and eﬀective anti-CHIKV agents.
In this paper, we shed the light to the convergent synthesis of
a new series of 2-arylidene thiazolo[3,2-a]pyrimidines. Using
simple synthons, namely 6-ethylthiouracil, bromoacetic acid
and diﬀerent aldehydes in a mixture of acetic acid/acetic
anhydride and catalytic amount of anhydrous sodium acetate,
a novel series of (Z)-7-ethyl-2-arylidine-5H-thiazolo[3,2-a]pyrim-
idine-3,5(2H)-diones was achieved. Optimization of the multi
component reaction conditions by replacing chloroacetic acid
with the more regioselective bromoacetic acid, lowering reac-
tion temperature and changing the mode of addition and we
were able to prepare one isomer at each case. X-ray crystal
structure of compound 12 shows that only one regioselective
isomer formed with the Z conguration that is potentially
stabilized by two intramolecular hydrogen bonds. Antiviral
activity evaluation demonstrated the tailed thiazolopyrimidine
15 as a candidate for future development.
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